NCT04985851View on ClinicalTrials.gov

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

NAActive, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

June 1, 2024

Study Completion Date

December 1, 2024

Conditions
Extensive-Stage Small-Cell Lung Cancer
Interventions
DRUG

durvalumab + anlotinib

Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.

DRUG

Durvalumab

durvalumab

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER